Status and phase
Conditions
Treatments
About
This study is designed to assess the safety and tolerability of single, escalating oral doses and repeat oral doses (7 days, once daily) of GSK835726 in healthy male subjects
Full description
A double-blind, placebo controlled, randomized cross-over single dose escalation study and a double-blind, placebo controlled, randomised parallel group 7-days once daily repeat dose study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of oral H1/H3 dual antagonist compound in healthy male subjects
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study.
The subject has a history of drug or any other allergy, which, in the opinion of the Investigator or appropriately qualified designee, contraindicates their participation, including known or suspected personal history or family history of adverse reactions or hypersensitivity to anti histamines.
The subject has participated in a study with a new molecular entity during the previous 3 months or any other study during the previous 2 months.
The subject regularly, or on average, drinks more than 21 units of alcohol a week or more than an average intake of 3 units per day (One unit = 125ml wine or 25ml spirits or 250ml normal strength lager).
The subject is currently taking regular (or a course of) medication, prescribed (including all anti-allergy medication) or not (including over the counter medication or herbal remedies such as St Johns Wort). Paracetamol is an exception and will be permitted at daily doses of up to 4g following all doses of investigational product.
The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
The subject has tested positive for HIV.
The subject has a positive drugs of abuse and alcohol test.
Donation of blood (450 mL or more) within 2 months of screening.
Donation during the study would result in >500mL of blood being donated over a 56 day period
Significant cardiac conduction abnormalities on two or more ECG tracings separated by at least 5 minutes at screening, including:
Subjects with Perennial Allergic Rhinitis (PAR) and Seasonal Allergic Rhinitis (SAR), unless subjects with SAR are asymptomatic and it is outside of the pollen season
Subjects with dermatographism and other skin conditions that might interfere with the wheal and flare test.
Subjects who are unable to comply with study procedures.
29 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal